XSHE
002287
Market cap1.65bUSD
Oct 09, Last price
19.56CNY
1D
1.14%
1Q
-2.40%
Jan 2017
-42.66%
IPO
16.57%
Name
Tibet Cheezheng Tibetan Med Co Ltd
Chart & performance
P/E
17.32
P/S
4.63
EPS
1.13
Div yield, %
4.24%
Shrs. gr., 5y
0.54%
Rev. gr., 5y
6.41%
Revenues
2.42b
+3.34%
Net income
646m
+10.98%
CFO
730m
+59.76%
Dividend
Sep 23, 20260.23 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tibet Cheezheng Tibetan Medicine Co., Ltd., along with its affiliated entities, specializes in the entire lifecycle of traditional Tibetan pharmaceuticals, from their research and development to manufacturing and distribution across China. The company's diverse range of drug products addresses various medical conditions, including those impacting the cardiovascular, respiratory, digestive, nervous, and musculoskeletal systems, as well as urinary, reproductive, and gynecological health. Established in 1995, the firm is headquartered in Nyingchi, China, and operates as a subsidiary of Gansu Qizheng Industry Group Co., Ltd.
Key people
Weidian Wang
Vice President · since 2016
Kailie Liu
General Manager, Director · since 2011
Ping Feng
Director of Human Resources · since 2011
Weiwu Chen
Chief R&D Officer
Huanli Cao
Secretary of the Board · since 2011
Bianbaciren
Director
Jufang Lei
Chairman of the Board · since 2010
Zhiqiang Wang
Chief Administrative Officer, Director · since 2010
Gesangsuolang
Independent Director
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑00 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||||
Revenues | |||||||||||||
Cost of revenue | |||||||||||||
Unusual Expense (Income) | |||||||||||||
NOPBT | |||||||||||||
NOPBT Margin | |||||||||||||
Operating Taxes | |||||||||||||
Tax Rate | |||||||||||||
NOPAT | |||||||||||||
Net income | |||||||||||||
Dividends | |||||||||||||
Dividend yield | |||||||||||||
Proceeds from repurchase of equity | |||||||||||||
BB yield | |||||||||||||
| Debt | |||||||||||||
Debt current | |||||||||||||
Long-term debt | |||||||||||||
Deferred revenue | |||||||||||||
Other long-term liabilities | |||||||||||||
Net debt | |||||||||||||
| Cash flow | |||||||||||||
Cash from operating activities | |||||||||||||
CAPEX | |||||||||||||
Cash from investing activities | |||||||||||||
Cash from financing activities | |||||||||||||
FCF | |||||||||||||
| Balance | |||||||||||||
Cash | |||||||||||||
Long term investments | |||||||||||||
Excess cash | |||||||||||||
Stockholders' equity | |||||||||||||
Invested Capital | |||||||||||||
ROIC | |||||||||||||
ROCE | |||||||||||||
| EV | |||||||||||||
Common stock shares outstanding | |||||||||||||
Price | |||||||||||||
Market cap | |||||||||||||
EV | |||||||||||||
EBITDA | |||||||||||||
EV/EBITDA | |||||||||||||
Interest | |||||||||||||
Interest/NOPBT | |||||||||||||